Qlife Holding AB's EBIT per Share for the
three
months ended in Mar. 2026 was kr-0.67.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was kr-2.17.
During the past 3 years, the average EBIT per Share Growth Rate was 89.20% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 84.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Qlife Holding AB's EBIT per Share or its related term are showing as below:
OSTO:QLIFE'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 31.7 Med: 89.2 Max: 97.7
Current: 89.2
During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of Qlife Holding AB was 97.70% per year. The lowest was 31.70% per year. And the median was 89.20% per year.
OSTO:QLIFE's 3-Year EBIT Growth Rate is ranked better than 97.97% of 690
companies
in the Medical Devices & Instruments industry
Industry Median: 9.5
vs OSTO:QLIFE: 89.20
Qlife Holding AB's EBIT for the
three
months ended in Mar. 2026 was kr-5.82 Mil.
Qlife Holding AB (OSTO:QLIFE) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Qlife Holding AB EBIT per Share Related Terms
Qlife Holding AB EBIT per Share Historical Data
* Premium members only.
The historical data trend for Qlife Holding AB's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-2.17
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qlife Holding AB (OSTO:QLIFE) has a EBIT per Share of kr-2.17 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Qlife Holding AB and its competitors. According to the industry distribution chart, Qlife Holding AB ranks #14 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 2%.
Is Qlife Holding AB's EBIT per Share too high?
Qlife Holding AB's current EBIT per Share is kr-2.17. Based on the distribution chart, Qlife Holding AB ranks #14 out of 690 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Qlife Holding AB has a GF Score™ of 15/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Qlife Holding AB's EBIT per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Qlife Holding AB ranks #14 out of 690 companies for EBIT per Share. This places Qlife Holding AB in the top 2% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 9.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.50, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Qlife Holding AB and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Qlife Holding AB's current EBIT per Share is kr-2.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qlife Holding AB stock overvalued right now?
Based on GuruFocus' analysis, Qlife Holding AB (OSTO:QLIFE) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.76, compared to a current price of kr1.92 — trading 152.9% above its estimated fair value. The current EBIT per Share is kr-2.17. Qlife Holding AB's overall GF Score™ is 15/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Qlife Holding AB (OSTO:QLIFE), the current EBIT per Share is kr-2.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Qlife Holding AB (OSTO:QLIFE) Overvalued in 2026?
Based on GuruFocus' analysis, Qlife Holding AB stock appears to be overvalued.
The current stock price of kr1.92 is trading 152.9% above its estimated GF Value™ of kr0.76.
GuruFocus considers Qlife Holding AB to be Significantly Overvalued.
Key valuation signals for OSTO:QLIFE:
EBIT per Share: kr-2.17
GF Value™: kr0.76 vs. price of kr1.92 (152.9% above fair value)
No single metric tells the full story. See the OSTO:QLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Qlife Holding AB is a medical device company that seeks to revolutionize the clinical biomarker testing of whole blood by taking it out of the lab and into the homes of the people who needs it. The Egoo Home System is an integrated platform consisting of a small home device and disposable capsules, each of which tests for a specific biomarker. It provides a digital infrastructure for sharing the data with the patient's doctor, clinic or hospital via smartphone and computer.
15GF Score
Get the complete analysis for OSTO:QLIFE
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:QLIFE has been successfully added to your 
